CORE LAB REPORTS SECOND QUARTER 2026 RESULTS
Rhea-AI Summary
Core Laboratories (NYSE: CLB) reported Q2 2026 revenue of $124.6 million, up 2% sequentially and down 4% year-over-year. GAAP operating income was $9.2 million and EPS $0.13; operating income ex-items was $9.4 million (8% margin) and EPS ex-items $0.11, up 42% and 85% sequentially, respectively, but lower year-over-year.
Reservoir Description generated revenue of $78.7 million (down 4% sequentially, 9% year-over-year) with 5% operating margin, pressured by Middle East and Russia-Ukraine disruptions. Production Enhancement delivered $45.9 million revenue (up 15% sequentially, 5% year-over-year) and ex-items operating margin of 12%.
Free cash flow was $3.1 million on cash from operations of $7.8 million and capital expenditures of $4.7 million. Core repurchased 214,712 shares for about $2.7 million, reduced net debt to $93.6 million, and reported a leverage ratio of 1.30. ROIC for Q2 2026 was 8.3%.
For Q3 2026, Core guides revenue to $128.5–$135.5 million, operating income to $10.5–$15.0 million (around 10% margin), and EPS to $0.12–$0.20. The Board declared a $0.01 per share dividend payable August 31, 2026.
Positive
- Revenue $124.6M, up 2% sequentially in Q2 2026
- Operating income ex-items $9.4M, up 42% sequentially
- EPS ex-items $0.11, up 85% sequentially in Q2 2026
- Production Enhancement revenue $45.9M, up 15% sequentially and 5% year-over-year
- Free cash flow $3.1M with cash from operations rising to $7.8M
- Net debt reduced to $93.6M, leverage ratio at 1.30
- 214,712 shares repurchased for about $2.7M in Q2 2026
- Q3 2026 revenue guidance $128.5M–$135.5M, implying sequential growth
Negative
- Revenue down 4% year-over-year in Q2 2026
- Operating income ex-items down 36% year-over-year in Q2 2026
- EPS ex-items down 42% year-over-year in Q2 2026
- Reservoir Description revenue $78.7M, down 4% sequentially and 9% year-over-year
- Geopolitical conflicts in Middle East and Russia-Ukraine disrupted projects and crude assay activity
- Higher capital expenditures $4.7M reduced free cash flow to $3.1M
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Q1 earnings report | Negative | -15.3% | Middle East conflict and severe weather pressured results; free cash flow remained low. |
| Feb 04 | Q4 earnings report | Positive | -4.2% | Revenue and annual cash flow improved, with debt reduction and repurchases announced. |
| Oct 22 | Q3 earnings report | Positive | +28.8% | Strong quarterly results, cash generation, debt reduction, and acquisition supported the release. |
| Jul 23 | Q2 earnings report | Positive | +5.9% | Revenue growth, stronger margins, free cash flow, and debt reduction accompanied the results. |
| Apr 23 | Q1 earnings report | Negative | -3.8% | Revenue declined amid geopolitical conflicts, sanctions, and seasonal operating pressure. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings reactions were mostly aligned with reported direction, with one notable divergence after Q4 2025 results.
Key Terms
gaap financial
non-gaap financial measure financial
free cash flow financial
return on invested capital financial
tubing conveyed perforating technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- REVENUE OF $124.6 MILLION, UP
2% SEQUENTIALLY AND DOWN4% YEAR-OVER-YEAR - OPERATING INCOME OF $9.2 MILLION; EX-ITEMS,
$9.4 MILLION 42% SEQUENTIALLY AND DOWN36% YEAR-OVER-YEAR - GAAP EARNINGS PER SHARE OF
$0.13 $0.11 85% SEQUENTIALLY AND DOWN42% YEAR-OVER-YEAR - FREE CASH FLOW OF $3.1 MILLION
- COMPANY REPURCHASED 214,712 SHARES OF COMMON STOCK, FOR
$2.7 MILLION - COMPANY ANNOUNCES Q3 2026 QUARTERLY DIVIDEND
Core's CEO, Larry Bruno, stated, "Our second quarter results displayed sequential improvement in revenue, operating income and earnings per share despite continued geopolitical conflicts that affected portions of our business, particularly Reservoir Description. Notably, we saw improvement in activity in
"As mentioned, client operations were disrupted in the
Reservoir Description
Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately
During the second quarter of 2026, Core Lab was engaged to support multiple exploration, appraisal, and carbon storage projects across
In
Also in
Collectively, these second quarter engagements highlight Core Lab's ability to leverage its global laboratory network, specialized technical expertise, and proprietary technologies to deliver advanced reservoir evaluation solutions for complex exploration, appraisal, and development projects.
Production Enhancement
Production Enhancement operations, which are focused on complex completions in unconventional oil and gas reservoirs in the
During the second quarter of 2026, a national oil company ("NOC") in
Also during the second quarter, Core Lab received regulatory approval to deploy its proprietary SpectraStim™ proppant tracing and SpectraScan® spectral gamma ray logging technologies in the
Liquidity, Free Cash Flow, Share Repurchases, and Dividend
Core continues to focus on maximizing free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the second quarter of 2026, cash from operations was
As mentioned in the Company's prior earnings releases, in February 2024, fire damaged a building on the campus of Core Lab's Advanced Technology Center in
In the second quarter of 2026, Core Lab repurchased 214,712 shares at an aggregate purchase price of approximately
As of June 30, 2026, Core's net debt (defined as long-term debt less cash and cash equivalents) was
On April 29, 2026, Core's Board of Directors ("Board") announced a quarterly cash dividend of
On July 29, 2026, the Board approved a cash dividend of
Return On Invested Capital
The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promotes capital efficiency and are designed to produce more predictable and superior long-term ROIC.
The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield services companies listed as Core's Comp Group by Bloomberg, as the Company continues to believe superior ROIC will result in higher total shareholder return. Using Bloomberg's formula, Core Lab's ROIC for the second quarter of 2026 was
Industry and Core Lab Outlook and Guidance
As a result of the ongoing conflicts in the
The long-term need for investment in new sources of production and initiatives to maximize recovery from existing producing fields remains strong. Accelerating decline rates from existing producing fields, together with geopolitical uncertainty, reinforce the importance of energy security and geographically diversified sources of hydrocarbon supply. Collectively, these factors are expected to support continued client investment in hydrocarbon development and new exploration.
Despite client activity headwinds from the two ongoing geopolitical conflicts, Core Lab expects third quarter revenue to increase sequentially, supported by improvement in several international regions, including the South Atlantic Margin and
While the timing of recovery in certain
Reservoir Description's third quarter 2026 revenue is projected to range from
The Company's guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange, and assumes an effective tax rate of
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's second quarter 2026 earnings announcement. The call will begin at 7:30 a.m. CDT / 8:30 a.m. EDT on Thursday, July 30, 2026. To access the listen-only webcast, visit www.corelab.com/investors 15 minutes before the start of the call. For those not available to listen to the live webcast, a replay and transcript will be available on the Company's website shortly after the call. Analysts may contact investor.relations@corelab.com for conference call dial-in information.
Core Laboratories Inc. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements Core Lab makes, includes forward-looking statements regarding the Company's future revenue, profitability, business strategies and developments, demand for the Company's products and services and for products and services of the oil and gas industry generally, made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business and general economic conditions, including inflationary pressures, the impact of tariffs, supply chain disruptions, trade policies and sanctions, international civil unrest or geopolitical tensions, including the continuing armed conflict between Russia and Ukraine, escalation of military conflict between the United States, Israel and Iran, and political conditions in South America, most recently in Venezuela, severe weather events, the severity and duration of public health crises, and any related actions taken by businesses and governments, and other factors as more fully described in the Company's most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. These important factors could cause the Company's actual results to differ materially from those described in these forward-looking statements. Such statements are based on current expectations of the Company's performance and are subject to a variety of factors, some of which are not under the control of the Company. Because the information herein is based solely on data currently available, and because it is subject to change as a result of changes in conditions over which the Company has no control or influence, such forward-looking statements should not be viewed as assurance regarding the Company's future performance.
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.
Visit the Company's website at www.corelab.com.
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) | ||||||||||||||||
Three Months Ended | % Variance | |||||||||||||||
June 30, | March 31, | June 30, | vs. Q1-26 | vs. Q2-25 | ||||||||||||
REVENUE | $ | 124,609 | $ | 121,797 | $ | 130,159 | 2.3 % | (4.3) % | ||||||||
OPERATING EXPENSES: | ||||||||||||||||
Costs of services and product sales | 101,371 | 102,073 | 103,701 | (0.7) % | (2.2) % | |||||||||||
General and administrative expense | 10,953 | 14,718 | 10,464 | (25.6) % | 4.7 % | |||||||||||
Depreciation and amortization | 3,825 | 3,764 | 3,670 | 1.6 % | 4.2 % | |||||||||||
Other (income) expense, net | (691) | (645) | (2,967) | NM | NM | |||||||||||
Total operating expenses | 115,458 | 119,910 | 114,868 | (3.7) % | 0.5 % | |||||||||||
OPERATING INCOME | 9,151 | 1,887 | 15,291 | 384.9 % | (40.2) % | |||||||||||
Interest expense | 2,846 | 2,891 | 2,711 | (1.6) % | 5.0 % | |||||||||||
Income (loss) before income taxes | 6,305 | (1,004) | 12,580 | NM | (49.9) % | |||||||||||
Income tax (benefit) expense | 507 | (251) | 1,911 | NM | (73.5) % | |||||||||||
Net income (loss) | 5,798 | (753) | 10,669 | NM | (45.7) % | |||||||||||
Net income (loss) attributable to non- | (158) | 36 | 33 | NM | NM | |||||||||||
Net income (loss) attributable to Core | $ | 5,956 | $ | (789) | $ | 10,636 | NM | (44.0) % | ||||||||
Diluted earnings (loss) per share | $ | 0.12 | $ | (0.02) | $ | 0.23 | NM | (47.8) % | ||||||||
Diluted earnings (loss) per share | $ | 0.13 | $ | (0.02) | $ | 0.22 | NM | (40.9) % | ||||||||
Diluted weighted average common | 46,878 | 46,073 | 47,364 | 1.7 % | (1.0) % | |||||||||||
Effective tax rate | 8 | % | 25 | % | 15 | % | NM | NM | ||||||||
SEGMENT INFORMATION: | ||||||||||||||||
Revenue: | ||||||||||||||||
Reservoir Description | $ | 78,747 | $ | 81,931 | $ | 86,280 | (3.9) % | (8.7) % | ||||||||
Production Enhancement | 45,862 | 39,866 | 43,879 | 15.0 % | 4.5 % | |||||||||||
Consolidated | $ | 124,609 | $ | 121,797 | $ | 130,159 | 2.3 % | (4.3) % | ||||||||
Operating income: | ||||||||||||||||
Reservoir Description | $ | 3,678 | $ | 1,146 | $ | 12,203 | 220.9 % | (69.9) % | ||||||||
Production Enhancement | 5,228 | 804 | 3,148 | 550.2 % | 66.1 % | |||||||||||
Corporate and Other | 245 | (63) | (60) | NM | NM | |||||||||||
Consolidated | $ | 9,151 | $ | 1,887 | $ | 15,291 | 384.9 % | (40.2) % | ||||||||
"NM" means not meaningful | ||||||||||||||||
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) | ||||||
Six Months Ended June 30, | % Variance | |||||
2026 | 2025 | |||||
REVENUE | (2.9) % | |||||
OPERATING EXPENSES: | ||||||
Costs of services and product sales | 203,444 | 203,170 | 0.1 % | |||
General and administrative expense | 25,671 | 24,111 | 6.5 % | |||
Depreciation and amortization | 7,589 | 7,387 | 2.7 % | |||
Other (income) expense, net | (1,336) | (632) | NM | |||
Total operating expenses | 235,368 | 234,036 | 0.6 % | |||
OPERATING INCOME | 11,038 | 19,708 | (44.0) % | |||
Interest expense | 5,737 | 5,313 | 8.0 % | |||
Income before income taxes | 5,301 | 14,395 | (63.2) % | |||
Income tax expense | 256 | 3,657 | (93.0) % | |||
Net income | 5,045 | 10,738 | (53.0) % | |||
Net income (loss) attributable to non-controlling interest | (122) | 256 | NM | |||
Net income attributable to Core Laboratories Inc. | (50.7) % | |||||
Diluted earnings per share | (52.2) % | |||||
Diluted earnings per share attributable to Core Laboratories Inc. | (50.0) % | |||||
Diluted weighted average common shares outstanding | 46,954 | 47,509 | (1.2) % | |||
Effective tax rate | 5 % | 25 % | NM | |||
SEGMENT INFORMATION: | ||||||
Revenue: | ||||||
Reservoir Description | (3.9) % | |||||
Production Enhancement | 85,728 | 86,567 | (1.0) % | |||
Total | (2.9) % | |||||
Operating income: | ||||||
Reservoir Description | (66.8) % | |||||
Production Enhancement | 6,032 | 4,651 | 29.7 % | |||
Corporate and Other | 182 | 515 | NM | |||
Total | (44.0) % | |||||
"NM" means not meaningful | ||||||
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) | ||||||||||||||||
% Variance | ||||||||||||||||
ASSETS: | June 30, | March 31, | December 31, | vs. Q1-26 | vs. Q4-25 | |||||||||||
Cash and cash equivalents | $ | 22,735 | $ | 22,819 | $ | 22,702 | (0.4) % | 0.1 % | ||||||||
Accounts receivable, net | 108,817 | 108,277 | 113,528 | 0.5 % | (4.1) % | |||||||||||
Inventories | 57,961 | 57,784 | 54,496 | 0.3 % | 6.4 % | |||||||||||
Other current assets | 24,847 | 25,491 | 23,939 | (2.5) % | 3.8 % | |||||||||||
Total current assets | 214,360 | 214,371 | 214,665 | — % | (0.1) % | |||||||||||
Property, plant and equipment, net | 100,390 | 99,985 | 99,447 | 0.4 % | 0.9 % | |||||||||||
Right of use assets | 52,870 | 54,708 | 54,346 | (3.4) % | (2.7) % | |||||||||||
Intangibles, goodwill and other long- | 219,158 | 218,664 | 215,552 | 0.2 % | 1.7 % | |||||||||||
Total assets | $ | 586,778 | $ | 587,728 | $ | 584,010 | (0.2) % | 0.5 % | ||||||||
LIABILITIES AND EQUITY: | ||||||||||||||||
Accounts payable | $ | 40,163 | $ | 39,982 | $ | 37,275 | 0.5 % | 7.7 % | ||||||||
Short-term operating lease liabilities | 11,940 | 12,097 | 11,456 | (1.3) % | 4.2 % | |||||||||||
Other current liabilities | 48,947 | 52,655 | 57,284 | (7.0) % | (14.6) % | |||||||||||
Total current liabilities | 101,050 | 104,734 | 106,015 | (3.5) % | (4.7) % | |||||||||||
Long-term debt, net | 113,861 | 114,460 | 110,255 | (0.5) % | 3.3 % | |||||||||||
Long-term operating lease liabilities | 39,314 | 41,285 | 42,309 | (4.8) % | (7.1) % | |||||||||||
Other long-term liabilities | 53,784 | 52,105 | 53,223 | 3.2 % | 1.1 % | |||||||||||
Total equity | 278,769 | 275,144 | 272,208 | 1.3 % | 2.4 % | |||||||||||
Total liabilities and equity | $ | 586,778 | $ | 587,728 | $ | 584,010 | (0.2) % | 0.5 % | ||||||||
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | ||||||||
Six Months Ended June 30, | ||||||||
2026 | 2025 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net income | $ | 5,045 | $ | 10,738 | ||||
Adjustments to reconcile net income (loss) to net cash provided by operating | ||||||||
Stock-based compensation | 5,934 | 4,697 | ||||||
Depreciation and amortization | 7,589 | 7,387 | ||||||
Changes in value of life insurance policies | (1,281) | (834) | ||||||
Deferred income taxes | (1) | (3,167) | ||||||
Accounts receivable | 4,619 | (3,717) | ||||||
Inventories | (3,897) | (1,991) | ||||||
Accounts payable | 3,257 | 6,647 | ||||||
Accrued expenses | (8,420) | (886) | ||||||
Other adjustments to net income | (1,071) | 1,709 | ||||||
Net cash provided by operating activities | 11,774 | 20,583 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Capital expenditures - operations | (8,135) | (6,259) | ||||||
Capital expenditures - rebuilding of | (2,524) | (1,648) | ||||||
Net proceeds from insurance recovery - | — | 4,678 | ||||||
Acquisitions, net of cash acquired | — | (617) | ||||||
Proceeds from sale of assets | 3,074 | 2,196 | ||||||
Net proceeds on life insurance policies | 252 | 778 | ||||||
Other investing activities | 11 | — | ||||||
Net cash used in investing activities | (7,322) | (872) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Repayment of long-term debt | (77,625) | (27,000) | ||||||
Proceeds from long-term debt | 81,000 | 25,000 | ||||||
Dividends paid | (920) | (938) | ||||||
Repurchase of common stock | (6,688) | (4,761) | ||||||
Other financing activities | (186) | 19 | ||||||
Net cash used in financing activities | (4,419) | (7,680) | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | 33 | 12,031 | ||||||
CASH AND CASH EQUIVALENTS, beginning of period | 22,702 | 19,157 | ||||||
CASH AND CASH EQUIVALENTS, end of period | $ | 22,735 | $ | 31,188 | ||||
Non-GAAP Information
Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the Securities and Exchange Commission.
Reconciliation of Operating Income, Net Income (Loss) and Diluted Earnings (Loss) Per Share (In thousands, except per share data) (Unaudited) | ||||||||||||
Operating Income | ||||||||||||
Three Months Ended | ||||||||||||
June 30, | March 31, | June 30, | ||||||||||
GAAP reported | $ | 9,151 | $ | 1,887 | $ | 15,291 | ||||||
Stock compensation (1) | — | 3,687 | — | |||||||||
Inventory and asset write-downs, lease termination, | — | 650 | 799 | |||||||||
Insurance recovery on property, plant and equipment (3) | — | — | (1,557) | |||||||||
Foreign exchange losses (gains) | 219 | 379 | 7 | |||||||||
Excluding specific items | $ | 9,370 | $ | 6,603 | $ | 14,540 | ||||||
Net Income (Loss) Attributable to Core Laboratories Inc. | ||||||||||||
Three Months Ended | ||||||||||||
June 30, | March 31, | June 30, | ||||||||||
GAAP reported | $ | 5,956 | $ | (789) | $ | 10,636 | ||||||
Stock compensation (1) | — | 2,765 | — | |||||||||
Inventory and asset write-downs, lease termination, | — | 487 | 599 | |||||||||
Insurance recovery on property, plant and equipment (3) | — | — | (1,168) | |||||||||
Foreign exchange losses (gains) | 165 | 285 | 5 | |||||||||
Effect of higher (lower) tax rate (4) | (1,070) | — | (1,234) | |||||||||
Excluding specific items | $ | 5,051 | $ | 2,748 | $ | 8,838 | ||||||
Diluted Earnings (Loss) Per Share Attributable to Core Laboratories Inc. | ||||||||||||||||
Three Months Ended | Six Months | |||||||||||||||
June 30, | March 31, | June 30, | June 30, | |||||||||||||
GAAP reported | $ | 0.13 | $ | (0.02) | $ | 0.22 | $ | 0.11 | ||||||||
Stock compensation (1) | — | 0.06 | — | 0.06 | ||||||||||||
Inventory and asset write-downs, lease | — | 0.01 | 0.01 | 0.01 | ||||||||||||
Insurance recovery on property, plant and | — | — | (0.02) | — | ||||||||||||
Foreign exchange losses (gains) | — | 0.01 | — | 0.01 | ||||||||||||
Effect of higher (lower) tax rate (4) | (0.02) | — | (0.02) | (0.02) | ||||||||||||
Excluding specific items | $ | 0.11 | $ | 0.06 | $ | 0.19 | $ | 0.17 | ||||||||
(1) The three months ended March 31, 2026 and six months ended June 30, 2026 includes the acceleration of stock compensation expense | ||||||||||||||||
(2) The three months ended March 31, 2026 and six months ended June 30, 2026 includes the write-down of leasehold improvements and | ||||||||||||||||
(3) The three months ended June 30, 2025 includes an insurance recovery associated with the fire at the | ||||||||||||||||
(4) The three months ended June 30, 2025 reflects tax expense at a normalized rate of | ||||||||||||||||
Segment Information (In thousands) (Unaudited) | ||||||||||||
Operating Income | ||||||||||||
Three Months Ended June 30, 2026 | ||||||||||||
Reservoir | Production | Corporate and | ||||||||||
GAAP reported | $ | 3,678 | $ | 5,228 | $ | 245 | ||||||
Foreign exchange losses (gains) | 70 | 112 | 37 | |||||||||
Excluding specific items | $ | 3,748 | $ | 5,340 | $ | 282 | ||||||
Return on Invested Capital
Return on Invested Capital ("ROIC") is presented based on management's belief that this non-GAAP measure is useful information to investors and management when comparing profitability and the efficiency with which capital has been employed over time relative to other companies. The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.
ROIC of
Free Cash Flow
Core uses the non-GAAP financial measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less cash paid for capital expenditures - operations. Management believes that free cash flow provides useful information to investors regarding the cash available in the period in excess of Core's needs to fund its capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative to operating income, net income, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash does not represent residual cash available for distribution because Core may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.
Computation of Free Cash Flow (In thousands) (Unaudited) | |||||||||
Three Months Ended | Six Months Ended | ||||||||
June 30, 2026 | June 30, 2026 | ||||||||
Net cash provided by operating activities | $ | 7,809 | $ | 11,774 | |||||
Capital expenditures - operations | (4,687) | (8,135) | |||||||
Free cash flow | $ | 3,122 | $ | 3,639 | |||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-second-quarter-2026-results-302838228.html
SOURCE Core Laboratories Inc